|Bid||5.35 x 1000|
|Ask||0.00 x 1100|
|Day's Range||4.69 - 6.10|
|52 Week Range||3.34 - 12.17|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A breakthrough approach for treatment of autoimmune and inflammatory diseases
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION . UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Tiziana Life Sciences plc , a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase 2a clinical data exhibiting impressive clinical activity of Milciclib monotherapy in patients with advanced Sorafenib-resistant or -intolerant patients with unresectable or metastatic hepatocellular ...
Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti
LOS ANGELES, CA / ACCESSWIRE / May 28, 2018 / Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation ...
NEW YORK & LONDON-- -- 80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use grounds Independent Data Monitoring Committee finds no unexpected signs or signals of toxicity Top line data expected Q3 2019 Tiziana Life Sciences plc , a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation ...
AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today announced that it has submitted* an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers. Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), is being developed for the treatment of autoimmune and inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).